← All trials
NCT05533892
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2022
- Primary completion
- Aug 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Sep 9, 2022
- Last posted
- Sep 9, 2022
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- BeOne MedicinesCollaborator
- Geneplus-Beijing Co. Ltd.Collaborator
- Haplox Biotechnology Co., Ltd.Collaborator
- Simcere Pharmaceutical Co., LtdCollaborator
- Huazhong University of Science and TechnologySponsor investigator
- Huazhong University of Science and TechnologyStudy chair
- Yuce Biotechnology Co., Ltd.Collaborator
- Government of ChinaCollaborator
- Huazhong University of Science and TechnologyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.